News

Novo Nordisk wins case to kick knockoff Ozempic off the market, but it may not last
Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.
Lawsuit alleges Maryland man with diabetes became blind after taking Ozempic
A man who took Ozempic and then became legally blind is suing the manufacturer, arguing it should have warned patients that ...
US Man Becomes Blind After Taking Ozempic Due to a Rare Eye Condition
An elderly American man has become completely blind after he was prescribed to take Ozempic to manage his type 2 diabetes.
GLP-1 copycats lose court battle
A federal judge's ruling essentially blocks compound pharmacies from selling less-expensive, unapproved versions of Ozempic ...
pharmaphorum21h
Novo Nordisk will file semaglutide for MASH next year
Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...
Health and Me on MSN18h
US Man Became Blind After Consuming Ozempic: Do Weight Loss Drugs Cause Blindness?
Todd Engel, a Maryland man, is suing Ozempic maker Novo Nordisk after allegedly going blind due to the drug, raising concerns ...
pharmaphorum21h
FDA fast-tracks GSK’s chronic hep B therapy bepirovirsen
Other drugs in development for CHB include Dicerna (now part of Novo Nordisk) and Roche’s siRNA candidate xalnesiran, which reported phase 2 data at the AASLD conference last year, and Arrowhead ...